Recent Articles in CRO/CMO Services

Fountain Medical, a global clinical CRO headquartered in Beijing, raised $62 million in a Series D financing led by Goldman Sachs, with Lilly Asia Ventures a co-investor. Founded in 2007, Fountain Medical said it would use the proceeds to expand its offerings around the world. With the growth of biopharma development in China, the company offers global clinical CRO services to China and ex-China biopharmas. China's CRO industry is growing quickly, the company said, spurred by its adoption of global regulatory standards over the past few years. More details.....

Share this with colleagues:

Taimei Technology, a Shanghai-Jiaxing SAAS company, completed a $212 million Series E/E+ round to advance its cloud AI-based suite of clinical trial programs. The company says its platform enables clinical research collaboration between sponsors, sites, CROs, patients, regulatory agencies and third-party providers. Founded in 2013, Taimei already offers six technology-enabled programs: data management, project management, electronic regulatory submission, central medical imaging, pharmacovigilance and drug logistics. It plans to expand into other areas of life science R&D. More details....

Share this with colleagues:

Guangzhou Boji Medical Biotech, a CRO, formed a JV with Great Bay Bio of Hong Kong to develop GBB101, a novel long-acting injectable biologic designed to treat anemia caused by chronic kidney disease. Great Bay is an AI-based CMC CDMO focused on innovative biologics. The two companies, which expect GBB101 to be one of the first long-acting anti-anemia products from a China biopharma, will each invest capital in the JV, though details were not provided. More details....

Stock Symbols: (SHE: 300404)

Share this with colleagues:

dMed Biopharma, a Shanghai CRO that offers clinical trial services in China, the US and the EU, completed a Series B financing of nearly $50 million, led by Vivo Capital and joined by Legend Capital, Qiming Venture Partners and Lilly Asia Ventures. Launched three years ago, dMed considers itself a "next-gen" clinical CRO with efficient operations, IT services and expertise in cross-border global trials. The company has 600 employees. Recently, dMed acquired Target Health, a full service New York-based CRO, to expand its global offerings and add new technologies. More details....

Share this with colleagues:

Nanjing Frontier Bio will collaborate with Thermo Fisher Scientific to develop a novel treatment for human immunodeficiency virus (HIV), providing clinical trial supplies of the candidate. Frontier already has a China approved treatment for HIV, albuvirtide, but it is developing a second HIV treatment that it in-licensed from the Rockefeller University of New York City. Frontier's drug development is centered on a long-acting peptide platform designed to transform any peptide drug into a long-acting agent. More details....

Stock Symbol: (NYSE: TMO)

Share this with colleagues: